Bristol-Myers Squibb Co. (BMY)

46.98
NYSE : Health Technology
Prev Close 45.75
Day Low/High 45.78 / 47.06
52 Wk Low/High 42.48 / 63.69
Avg Volume 12.92M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 74.84B
EPS 3.00
P/E Ratio 12.04
Div & Yield 1.64 (3.57%)
Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene's (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co.

Starboard Issues Statement On Bristol-Myers

Starboard Issues Statement On Bristol-Myers

NEW YORK, March 29, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a shareholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY), today provided the following statement on its investment...

Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote "FOR" Proposed Merger With Celgene

Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote "FOR" Proposed Merger With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today announced that independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co.

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Starboard Mails Letter To All Bristol-Myers Squibb Shareholders

Starboard Mails Letter To All Bristol-Myers Squibb Shareholders

Starboard Asks Shareholders to NOT Allow Bristol-Myers to Bet the Company on a Highly-Risky and Likely Value-Destructive Acquisition

Bristol-Myers Squibb Becomes #231 Most Shorted S&P 500 Component, Replacing Wynn Resorts

Bristol-Myers Squibb Becomes #231 Most Shorted S&P 500 Component, Replacing Wynn Resorts

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.

What More Do They Want?: Cramer's 'Mad Money' Recap (Monday 3/25/19)

What More Do They Want?: Cramer's 'Mad Money' Recap (Monday 3/25/19)

Apple couldn't do much to hold back the bears today, but Jim Cramer says the company's services segment is the most important thing and he's more than happy with it.

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets

Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition Of Celgene

Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition Of Celgene

Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits Of Pending Transaction With Celgene

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits Of Pending Transaction With Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG).

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia and Mellanox have many common customers, and also a major common competitor in Intel.

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Bristol-Myers Squibb To Announce Results For First Quarter 2019 On April 25, 2019

Bristol-Myers Squibb To Announce Results For First Quarter 2019 On April 25, 2019

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2019 on Thursday, April 25, 2019.

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Fear of Big Sellers: Cramer's 'Mad Money' Recap (Wed. 3/6/19)

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

Bristol-Myers Squibb To Take Part In The Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In The Barclays 2019 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Barclays 2019 Global Healthcare Conference on Wednesday, March 13, 2019, in Miami.

Starboard Mails Letter With Important Message To All Bristol-Myers Squibb Stockholders

Starboard Mails Letter With Important Message To All Bristol-Myers Squibb Stockholders

Reiterates Belief that the Proposed Merger with Celgene is Ill-Advised and Not in the Best Interests of Bristol-Myers Stockholders

Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene

Bristol-Myers Squibb Files Investor Presentation And Board Of Directors Sends Letter To Shareholders Regarding Pending Transaction With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today filed an investor presentation with the Securities and Exchange Commission (SEC), and the Board of Directors sent an open letter to the Company's shareholders regarding the previously announced definitive...

Bristol-Myers Squibb To Take Part In The Cowen And Company 39th Annual Health Care Conference

Bristol-Myers Squibb To Take Part In The Cowen And Company 39th Annual Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in a fireside chat at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, in Boston.

Let’s Explore the Reasons I Remain Sidelined

FAANG rallies are fine when breadth is playing along. FAANG rallies that suck the life out of other stocks (breadth) to feed themselves are bearish.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

TheStreet Quant Rating: C+ (Hold)